Expanded Access Program for Ivosidenib (AG-120) Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH1 Mutation

Trial Profile

Expanded Access Program for Ivosidenib (AG-120) Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH1 Mutation

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Ivosidenib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Expanded access; Therapeutic Use
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 14 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top